Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

E.D. Kwon; C.G. Drake; H.I. Scher; K. Fizazi; A. Bossi; A.J.M. van den Eertwegh; M. Krainer; N. Houede; R. Santos; H. Mahammedi; S. Ng; M. Di Maio; F.A. Franke; S. Sundar; N. Agarwal; A.M. Bergman; T.E. Ciuleanu; E. Korbenfeld; L. Sengelov; S. Hansen; C. Logothetis; T.M. Beer; M.B. McHenry; P. Gagnier; D. Liu; W. Gerritsen

doi:10.1016/S1470-2045(14)70189-5

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

E.D. Kwon, C.G. Drake, H.I. Scher, K. Fizazi, A. Bossi, A.J.M. van den Eertwegh, M. Krainer, N. Houede, R. Santos, H. Mahammedi, S. Ng, M. Di Maio, F.A. Franke, S. Sundar, N. Agarwal, A.M. Bergman, T.E. Ciuleanu, E. Korbenfeld, L. Sengelov, S. HansenC. Logothetis, T.M. Beer, M.B. McHenry, P. Gagnier, D. Liu, W. Gerritsen

Medical oncology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	700-712
Journal	Lancet Oncology
Volume	15
Issue number	7
DOIs	https://doi.org/10.1016/S1470-2045(14)70189-5
Publication status	Published - 2014

Access to Document

10.1016/S1470-2045(14)70189-5

Cite this

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., Ng, S., Di Maio, M., Franke, F. A., Sundar, S., Agarwal, N., Bergman, A. M., Ciuleanu, T. E., Korbenfeld, E., Sengelov, L., ... Gerritsen, W. (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, 15(7), 700-712. https://doi.org/10.1016/S1470-2045(14)70189-5

@article{fd74c32ceed244b6bda490405563db7e,

title = "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial",

author = "E.D. Kwon and C.G. Drake and H.I. Scher and K. Fizazi and A. Bossi and {van den Eertwegh}, A.J.M. and M. Krainer and N. Houede and R. Santos and H. Mahammedi and S. Ng and {Di Maio}, M. and F.A. Franke and S. Sundar and N. Agarwal and A.M. Bergman and T.E. Ciuleanu and E. Korbenfeld and L. Sengelov and S. Hansen and C. Logothetis and T.M. Beer and M.B. McHenry and P. Gagnier and D. Liu and W. Gerritsen",

year = "2014",

doi = "10.1016/S1470-2045(14)70189-5",

language = "Undefined/Unknown",

volume = "15",

pages = "700--712",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "7",

}

Kwon, ED, Drake, CG, Scher, HI, Fizazi, K, Bossi, A, van den Eertwegh, AJM, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Di Maio, M, Franke, FA, Sundar, S, Agarwal, N, Bergman, AM, Ciuleanu, TE, Korbenfeld, E, Sengelov, L, Hansen, S, Logothetis, C, Beer, TM, McHenry, MB, Gagnier, P, Liu, D & Gerritsen, W 2014, 'Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial', Lancet Oncology, vol. 15, no. 7, pp. 700-712. https://doi.org/10.1016/S1470-2045(14)70189-5

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. / Kwon, E.D.; Drake, C.G.; Scher, H.I. et al.

In: Lancet Oncology, Vol. 15, No. 7, 2014, p. 700-712.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

AU - Kwon, E.D.

AU - Drake, C.G.

AU - Scher, H.I.

AU - Fizazi, K.

AU - Bossi, A.

AU - van den Eertwegh, A.J.M.

AU - Krainer, M.

AU - Houede, N.

AU - Santos, R.

AU - Mahammedi, H.

AU - Ng, S.

AU - Di Maio, M.

AU - Franke, F.A.

AU - Sundar, S.

AU - Agarwal, N.

AU - Bergman, A.M.

AU - Ciuleanu, T.E.

AU - Korbenfeld, E.

AU - Sengelov, L.

AU - Hansen, S.

AU - Logothetis, C.

AU - Beer, T.M.

AU - McHenry, M.B.

AU - Gagnier, P.

AU - Liu, D.

AU - Gerritsen, W.

PY - 2014

Y1 - 2014

U2 - 10.1016/S1470-2045(14)70189-5

DO - 10.1016/S1470-2045(14)70189-5

M3 - Article

VL - 15

SP - 700

EP - 712

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 7

ER -

Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology. 2014;15(7):700-712. doi: 10.1016/S1470-2045(14)70189-5